Saturday Program

Simultaneous Sessions | Clinical Trial Update | Science in progress | Hematology-in-focus Session | Lunch Debates | Meet-the-Expert | 5th EHA / ASH Joint Symposium | EHA Business Meeting | Jean Bernard Lifetime Achievement Award | Presidential Symposium | Plenary Session 1 | Poster Session II

CLINICAL TRIAL UPDATE
08:00 – 09:15, Hall A2

MYELODYSPLASTIC SYNDROMES
Chair: M Cazzola (Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy)

- LENALIDOMIDE TRIALS
E Hellström-Lindberg (Karolinska Institute, Stockholm, Sweden)
- AZACITIDINE TRIALS
P Fenaux (Hôpital Avicenne Paris, Bobigny, France)
- AMG 531 (THROMBOPOIETIN-RECEPTOR AGONIST) TRIALS
T de Witte (Radbout University Nijmegen Medical Center, Nijmegen,
The Netherlands)
- SAFETY STUDIES OF ERYTHROPOIETIN & G-CSF ADMINISTRATION
M Cazzola (Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy)

CLINICAL TRIAL UPDATE
10:30 – 11:45, Hall A2

THROMBOSIS
Chair: H Büller (Academic Medical Center, Amsterdam, The Netherlands)

- ORAL DIRECT FACTOR XA INHIBITORS
A Kakkar (Thrombosis Research Institute, London, United Kingdom)
- ORAL DIRECT FACTO IIA INHIBITORS
G Agnelli (University of Perugia, Perugia, Italy)
- OTHER TARGETS
H Büller (Academic Medical Center, Amsterdam, The Netherlands)